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Objective: Tripterygium wilfordii Hook F (TwHF) is a widely used and effective treatment
for inflammatory diseases. There have been concerns about its toxicity but no adequate
synthesis of the evidence for adverse events (AEs). We aimed to undertake a clinically
informative, systematic safety profile of TwHF.
Methods: We undertook a systematic review and meta-analysis of experimental studies
and observational studies. We searched electronic databases and conference abstracts.
Safety outcomes were rates of common AEs.
Results: We screened 4137 abstracts for eligibility and included 594 studies in the
analysis. The overall incidence of AEs was 26.7% (95% CI 24.8%, 28.8%) in 23,256
TwHF users. The estimates did vary markedly when stratified by specific study types.
The incidence of gastrointestinal symptoms, adverse reproductive outcomes, adverse
skin reactions, hematologic events and cardiovascular events were 13.3% (95% CI
11.9%, 14.9%), 11.7% (95% CI 10.3%, 13.3%), 7.8% (95% CI 6.3–9.5%), 6.5% (95% CI
5.7–7.4 %) and 4.9% (95%CI 1.6 %, 14.3 %), respectively. The prevalence of irregular
menstruation (IM) was increased in patients taking TwHF compared with those given
control (odds ratio [OR] 4.65, 95% CI 3.08 to 7.03). TwHF use has lower risk of weight
gain (OR 0.12 [95%CI 0.04 to 0.39]) and hair loss (OR 0.37 [95% CI 0.18 to 0.78]).
Furthermore, long-term aspirin use (>6months) has a higher AEs incidence (31.0% [95%
CI 24.5%–38.5%]).
Conclusion: Our findings suggest that more than one in four patients who were
taking TwHF had experienced AEs. A clear need exists for improved understanding of
contributing risk factors, as well as of prevention and management strategies to improve
patients’ tolerance for TwHF.
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INTRODUCTION
Tripterygium wilfordii Hook F (TwHF), a member of the
Celastraceae family, is a woody vine native to the south side
of the Tangtze River, China. For more than a decade, experts
from across the globe have been working on exploring the
effect of TwHF. There have been many studies published on
the potential use of this herb. As of June 1, 2016, about 200
journal articles related to TwHF had ten or more citations. These
in vitro and in vivo studies confirm the therapeutic benefits of
it. TwHF is used to be a novel immunosuppressive and anti-
inflammatory agent, especially for rheumatoid arthritis (RA)(Tao
et al., 2002; Goldbach-Mansky et al., 2009; Lv et al., 2015),
nephrotic syndrome (Xu et al., 2009), diabetic nephropathy(Ge
et al., 2013), and kidney transplantation(Ji et al., 2006). It has
also been reported as an antitumour agent (Wong et al., 2012). In
addition, reports discussed the role of TwHF in the treatment of
HIV/AIDS (Duan et al., 2000) and male fertility regulation(Qian,
1987).
Although efficacious, TwHF has some safety disadvantages
(Canter et al., 2006). Previous studies have demonstrated
the adverse menstrual effects, and TwHF might be most
appropriately used by patients who are postmenopausal or not
interested in fertility (Qian, 1987). Furthermore, TwHF can
impair liver and renal function and is not recommended for
use in patients with decreased liver or renal function. In April
2012, the State food and drug administration (China SFDA) has
issued the No 46 Adverse Drug Reaction Information Bulletin
to Tripterygium wilfordii preparations users (http://www.sda.
gov.cn/WS01/CL0078/70473.html; Accessed May 16, 2016).
However, this bulletin did not provide sufficient information
to clinicians. What is the incidence of adverse events (AEs) in
TwHF users?What are the characteristics and risk factors of AEs?
Published systematic reviews (SRs) usually put a strong emphasis
on efficacy and fail to investigate safety (Chen et al., 2010; Ernst,
2011). Randomized controlled trials (RCTs) have offered solace
for practitioners and their patients, relatively common adverse
effects vs. methotrexate (MTX) (Lv et al., 2015). Inconsistency
between observational studies and RCTs confuses researchers and
should be carefully interpreted (Canter et al., 2006). Whatever,
the history of long-term use does not well establish the safety of
TwHF.
Due to its anti-inflammatory and immunosuppressive effects
it may be comparable with MTX (Lv et al., 2015), TwHF may
be considered as an alternative or complementary therapy for
treatment of RA or other inflammatory diseases. It might lead
to wider use of TwHF. Clinicians and their patients therefore
need accurate evidence of harms. In this study, we performed
a comprehensive analysis of the current available evidence to
estimate the incidence of AEs and investigate the association
between TwHF use and reported major AEs, to provide a
clinically informative safety profile for TwHF.
Abbreviations: AE, adverse event; CCT, controlled clinical trial; MTX,
methotrexate; OR, Odds ratio; PSS, prospective single arm study; RA, rheumatoid
arthritis; RCT, randomized controlled trial; SR, systematic review; TwHF,
Tripterygium wilfordiiHook F.
METHODS
Study Protocol and Search Strategy
The study protocol has been registered with the International
Prospective Register for Systematic Reviews (PROSPERO) CRD
42014010186. This work followed the methods specified in
the Cochrane Handbook for Interventional Systematic Reviews
(Higgins et al., 2008). The Preferred Reporting Items for
Systematic Reviews andMeta-Analyses (PRISMA) statement was
used as a basis for reporting this work (Supplementary File 1).
We searched Pubmed, Embase, China National Knowledge
Infrastructure (CNKI), Wanfang, VIP, and Sionmed from their
inception to 16 January 2016 (Supplementary File 2). No
language restriction was applied. All relevant references were
checked for additional citations. Major conference abstracts were
hand-searched.
Study Selection
Abstracts and articles titles were reviewed by pairs of authors (CZ
and PPS), working independently. Once the articles were chosen,
inclusion was discussed by all authors to resolve differences
of opinion. Studies contained original data were included if
they investigated one or more AEs of interest. RCTs and
controlled clinical trials (CCTs) comparing TwHF with placebo,
no treatment, or other drug therapies were considered most
reliable if they included safety data, followed by cohort studies
and then case-control studies. In the absence of controlled
studies, we included prospective single arm studies (PSSs)
following up patients given TwHF and, finally, case series and
individual case reports. For redundant publication, we analyzed
only the most complete set of data to avoid double counting
cases.
Outcomes
The safety outcomes of this study were incidences of AEs.
The known AEs includes gastrointestinal symptoms, adverse
reproductive outcomes, cardiac damage, kidney and liver
damage, skin disorders, hair disorders, weight change and even
death. Incidence of AEs = (number of patients with AEs/total
patients studied)× 100%.
Data Collection
Data was abstracted independently by two authors (CZ and
PPS) using data extraction forms (Supplementary Files 3–7). All
disagreements were resolved through discussion with a third
reviewer (APL). The following variables were recorded: study
name, first author, date of publication, disease, interventions,
number of patients, duration of follow-up, age, gender, quality
aspects and all AEs profiles. For safety endpoints, we extracted
the number of events of interest and total number of patients in
each group.
Quality Assessment
Quality assessment was also independently performed by two
researchers (CZ and PPS), and disagreements were resolved by
consensus. Cochrane Collaboration’s risk of bias tool was used to
access the methodological quality of the included RCTs.
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Statistical Analysis
When appropriate, data from individual prospective studies were
pooled by meta-analysis with Metaanalyst Beta 3.13 and STATA
11.1 (Stata Corp, College Station, TX).We analyzed the incidence
of AEs obtained from different studies to determine the meta-
analytic weighted average and the 95% confidence interval (CI).
We used a random-effects model to perform the analysis in
order to take into account the heterogeneity of the studies. The
overall incidence was estimated as a weighted average, iteratively
calculating the weights and the heterogeneity variance they
depend upon. The odds ratios (ORs) compare the likelihood of
an AE between two groups. Heterogeneity between study-specific
estimates was investigated. Sensitivity analysis was carried out to
explore the effect of trial quality on overall results. Descriptive
method was applied to summarize the adverse outcomes of
TwHF for case series and case reports.
RESULTS
Study Characteristics
After screening 4137 citations, we reviewed 876 potentially
relevant full-text articles and identified 594 primary publications
(264 RCTs, 100 CCTs, 156 PSSs, 8 case series and 66 case reports)
(Figure 1) (Supplementary File 8). Baseline characteristics of
individual studies are summarized in Supplementary File 3–7.
In total, 48,536 patients were included in the qualitative
analysis.
264 RCTs recruited altogether 27,368 patients, with the
smallest sample size 13 and the largest size 3789. In 206 studies,
TwHFwas given to experimental group or both experimental and
control group, which included 17,265 patients. In the remaining
58 clinical studies, TwHF was allocated to control. In addition,
100 CCTs recruited 10,503 patients, the sample size ranges from
12 to 656. In 81 of 100 studies, TwHF was given in active group.
Totally 10,441 patients were included in 156 uncontrolled PSSs,
and sample size from 4 to 606. Eight case series reported 127
patients, and 66 case reports reported 97 cases.
The quality of evidence varied according to the Cochrane
Collaboration’s tool. The majority of the included studies had
unclear risk of bias (Supplementary File 9. Risk of bias graph).
Studies published in English, and Chinese were included.
No study in third language identified met inclusion criteria.
The research sittings were covering 94% of provincial level
regions (29/31, 22 provinces, four autonomous regions, and four
municipalities, except Tibet and Qinghai) in mainland China.
Onemulticenter study was done in 11 centers of the United States
(Goldbach-Mansky et al., 2009).
Considering a possible source of bias might the year of study,
we did an initial analysis of publication time trends. Figure 2
shows the results graphically and indicates that clinical study
design change occurred during 36-year span. This result seems
surprising since great changes have occurred over the last decades
in case series and case reports that nearly disappear. Perhaps,
RCTs are more likely to be accepted by the journals. Therefore,
when analyzing the association between TwHF and all reported
major AEs, we need to consider the influence of specific study
types for risk estimate.
Safety Outcomes
Generally, 428 studies presented 23,256 patients with 7616
events. 273 studies reported 2469 gastrointestinal upsets, 228
articles pointed 1663 adverse reproductive outcome, 79 papers
presented an increase of ALT was observed among 476 patients,
43 articles reported 193 events related to renal injury, 250
articles reported 773 adverse hematologic events, 10 papers
with 33 cardiovascular events. 108 studies accounted for 640
skin and mucosa AEs and 159 articles reported other events
include hair loss, weight loss and fatigue which amount
to 1007.
As shown in Figure 3, the weighted proportion of AEs was
26.7% (95% CI 24.8%, 28.8%) among patients with TwHF. The
results were the same in leave-one-out sensitivity analysis. 29.7%
(95% CI 22.1%, 38.7%) of pediatric patients and 26.5% (95%
CI 24.5%, 28.6%) of adults experienced AEs. The incidence of
AEs among combination therapy studies (25.1% [95% CI 23.0%,
27.3%]) was lower than amongmonotherapy studies (31.6% [95%
CI 27.2%, 36.3%]). The rate of AEs were 23.6% (95% CI 21.2%,
26.2%), 29.9% (95% CI 24.9%, 35.4%), 31.6% (95% CI 27.6%,
35.9%) among RCT, CCT, PSS designs studies. Results suggest
that the hierarchy of evidence could influence the incidence rate
of TwHF AEs. The role of TwHF in the trials, as a treatment in
interventional or control group, may be a potential risk factor.
Our estimate of AEs incidence was 21.8% (95% CI 19.1% to
24.9%), 29.8% (95% CI 25.4% to 34.6%), 29.1% (95% CI 23.5%
to 35.3%) and 32.7% (95% CI 22.7% to 44.4%) when restricted to
data from RCT treatment group (30 studies), RCT control group
(30 studies), CCT treatment group (30 studies), CCT control
group (30 studies), respectively.
In another subgroup analysis, the reported gastrointestinal
symptoms incidence was 13.3% (95%CI 11.9%, 14.9%), 14.8%
(95%CI 10.9%, 19.8%), 13.3% (95%CI 11.8%, 14.9%) of total
population, pediatric patients and adult patients respectively.
Meta-analysis showed gastrointestinal symptoms occur less
frequently with TwHF combination therapy (12.7% [95% CI
11.2% to 14.4%]) than in patients with monotherapy (13.8%
[95% CI 12.1% to 15.7%]). In RA patients, the combined rate of
all gastrointestinal symptoms was significantly lower in TwHF
combination therapy-treated patients than in conventional
treatment-treated patients (OR = 0.59, 95% CI, 0.46 to 0.76;
P < 0.001).
Total reproductive adverse events (RAE) incidence was 11.7%
(95% CI 10.3%, 13.3%) among TwHF users. Concerning specific
issues dealing with the safety of TwHF in children, six studies
examined RAE occurrence in minors. RAE incidence was 8.9%
(95%CI 1.9% to 33.2%) and 11.7% (95%CI 10.3% to 13.3%)
of pediatric and adult patients. Forty-four studies (n = 1207)
reported 133 cases of irregular menstruation (IM), IM incidence
was 12.7% (95%CI 10.1 to 15.8%). The prevalence of IM was
increased in patients taking TwHF compared with those given
control (OR 4.65, 95% CI 3.08 to 7.03; P < 0.001).
Ten studies reported cardiovascular events occurrence in 555
TwHF users. The rate of cardiovascular events was 4.9% (95%CI
1.6%, 14.3%). The meta-analytical yielded the frequency of ALT
elevation cases (greater than abnormal liver function) of 4843
patients in 78 studies was 8.6% (95%CI 6.8–10.7%). Incidence of
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FIGURE 1 | PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the systematic literature search. *Included
animal studies, non-biological science studies, and human studies of Tripterygium wilfordii Hook F (TwHF) not reporting adverse events (AEs). † Included 108 with no
records for AEs; 71 articles with TwHF as basic treatment; 31 research allocated the patients into different groups through registration number and 2 through
pathological type but all of them were rated as random trials; 37 duplicate publication of the same research; 7 articles with problems in the reporting like inconsistent
data; 12 plagiarized articles; 9 irrelevant and 5 articles with unclear source of the samples.
hematologic events and adverse skin reactions was 6.5% (95%CI
5.7–7.4%) and 7.8% (95%CI 6.3–9.5%), respectively.
Five studies reported weight changes, include 3 RCTs, 1 CCT
and 1 PSS. Compared to Prednisone (3 studies, n = 129), TwHF
use was associated with reduced weight gain incidence risk (OR
0.12 (95%CI 0.04 to 0.39; P = 0.001; heterogeneity I2 = 0). One
PSS (n= 13) suggested 1 case of weight loss only in TwHF group
whereas one CCT (n = 52) suggested 2 case of weight loss in
MTX group and no weight loss case in TwHF monotherapy or
combination therapy group.
Thirty-eight publications reported an AE of TwHF on hair
loss, 8 of which were case reports, 7 of which were PSSs. 15 RCTs
of TwHF (n = 383) vs. control (n = 402) reported hair loss in
eleven of 383 (2.9%) patients in the TwHF group compared with
38 of 404 (9.4%) in the control group. 8 CCTs reported hair loss
in one of 263 patients given TwHF vs. 13 of 309 given control
treatment. The incidence of hair loss was lower with TwHF than
with control treatment (n = 1357; OR 0.37, 95% CI 0.18 to 0.78,
P = 0.012; heterogeneity I2 = 25%).
TwHF users with treatment period of 6–12 months were
always exhibit the relatively high occurrence of AEs than
the shorter-term users (Table 1), all types of AEs other than
adverse skin reactions. Two RCTs (n = 248) compared AEs
between TwHF plus MTX with MTX monotherapy (Figure 4).
The combination group was greater than MTX group in
the incidence of gastrointestinal disorders, skin reaction, ALT
elevation and infection, but failed in leucocytopenia and irregular
menstruation.
Case Series and Case Reports
All case reports and case series were from mainland China.
Sixty-six case reports included 49 females and 46 males, and 2
unclear cases (Supplementary File 7). There were 7 cases less
than or equal to the age of 18 years old, 15 cases older than
60 years old. Of 97, death occurred in 9 patients following an
overdose of TwHF. Ten reports presented 10 cases with organ
failure, including 6 cases with acute renal failure and 4 cases of
TwHF-induced premature ovarian failure. Seven papers reported
11 cases of aplastic anemia. Four articles reported skin rashes,
including 2 cases of definite drug-induced rashes, 1 with allergic
urticarial and 1 with erythra. Three articles reported hair loss,
including 2 cases with diffuse hair loss and 1 temporary hair loss.
In case series, TwHF overdose in 59 patients with renal failure
were described. However, it is worth mentioning that 17 people
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FIGURE 2 | Time trend of 594 articles relevant to Tripterygium wilfordii Hook F (TwHF) adverse events (prospective studies vs. retrospective studies).
The search was performed on March 2016. RCT, randomized controlled trial; CCT, controlled clinical trial; PSS, prospective single arm study; CS, case series; CR,
case report.
FIGURE 3 | Random-effect pooled estimates of incidence of total adverse events, gastrointestinal symptoms, adverse reproductive outcomes and
their subsequent subgroup analyses, along with adverse skin reactions, hematologic events and cardiovascular events after Tripterygium wilfordii
Hook F (TwHF) therapy. Each color represents a different type of adverse event.
who attempted suicidal out of 59 patients are from remote rural
areas of western China which are likely to die with fresh root
portion of TwHF plant. It is also noteworthy that, the incidence
of fatal accident in past 10 years was the lowest in recorded
history.
DISCUSSION
To date, this is the most comprehensive analysis that specifically
deals with clinical safety of TwHF. This study, focusing on the
incidence, known or potential risk factors of TwHF AEs, is
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TABLE 1 | Incidence of adverse events of Tripterygium wilfordii Hook F and the length of treatment period.
Incidence of adverse Incidence of gastrointestinal Incidence of adverse Incidence of adverse Incidence of
events (%; 95% CI) symptoms (%; 95% CI) reproductive outcomes skin reactions ALT elevation
(%; 95% CI) (%; 95% CI) (%; 95% CI)
≤3 (months) 23.4 (20.6–26.3) 13.2 (11.1–15.6) 9.6 (8.0–11.6) 8.8 (6.4–11.9) 7.3 (5.3–10.0)
3 < Time ≤ 6 (months) 26.3 (21.6–31.6) 13.2 (10.2–16.9) 12.5 (9.1–16.9) 8.2 (5.3–12.5) 9.1 (5.9–13.8)
6 < Time ≤ 12 (months) 31.0 (24.5–38.5) 19.2 (14.4–25.3) 13.5 (8.5–20.8) 5.4 (3.1–9.0) 11.1 (2.9–34.0)
12 < Time (months) 31.2 (22.0–42.3) 13.3 (9.2–18.9) 7.8 (4.3–13.7) 4.4 (1.0–17.4) 4.8 (0.7–27.1)
FIGURE 4 | Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX) vs. methotrexate (MTX) alone adverse events dot plot with relative risk (n =
248). The right hand panel displays a relative risk plot, graphically presenting the relative risks, with associated 95% conference intervals, these helping to determine
risk relative to other signals.
aimed at informed clinical decision-making. Our findings suggest
that 26.7% TwHF users experienced AEs. These findings are
supported by evidence from 428 prospective studies.
A stratified analysis provides additional insight for known or
potential risk factors of TwHF AEs. First, the incidence of TwHF
AEs seems to increase over time, after TwHF therapy (Table 1),
although pooled estimates have shown that cases continue to
accumulate beyond this period but at a slower rate. Second,
there is substantial evidence to suggest that exposure to children
and monotherapy enhance the risk of AEs. These factors are
potential targets for the prevention of adverse outcomes. Finally,
as shown in Figure 2, the incidences of AEs are significantly
affected by study type. However, it is different from the results
of a methodological study which suggests that study type might
have no effect on AE incidence (Golder et al., 2011). Whether a
greater number of events are hidden by an inappropriate reading
of significance testing in RCTs? Clinicians and researchers must
consider the study design when interpreting and designing RCTs
of TwHF.
Results have suggested that TwHF may increase risk of
reproductive toxicity, adverse gastrointestinal complications, and
abnormal liver function (Figures 3, 4). According our findings
(Table 1), TwHF should not be used for prolonged periods of
time to increase risk of adverse reproductive outcomes. Despite
the availability of newer biological agents, RA patients were at a
higher risk of GAEs than the general population (Salliot and van
der Heijde, 2009). Combined results showed less GAEs in TwHF
combination therapy group than in MTX monotherapy groups.
TwHF combination therapy may enhance tolerability because
they reduce gastrointestinal toxicity of TwHF monotherapy.
Hence, the potential applications of combination therapy can
provide powerful clues as to the role in reducing harms. Our
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study indicated the frequency of ALT elevation (more than
normal) in TwHF users was 8.6% (95% CI 6.8–10.7%). A meta-
analysis suggested the prevalence of elevated liver enzymes (more
than twice upper limit of normal) is close to 13% of the patients
with MTX (Salliot and van der Heijde, 2009). Uncertainties exist
due to the limited amount of data in some of the other enzymes
found the liver (such as AST). In our included literatures, no
death was reported in prospective studies. All nine cases of
overdose mortality were from case reports. Totally, the potential
determinants of overdose death are both poorly understood and
studied.
Data on the risk for body weight have further questions. A
study, published in the journal Cell (Liu et al., 2015), found
that an extract in TwHF has a huge weight loss effect on obese
mice. However, animal experiment and clinical trial seem to
offer contradictory evidence on whether TwHF contribute to
mice weight loss or weight gain (Wang et al., 2000; Tao et al.,
2001). There are several factors might explain the association
between TwHF and weight loss. GAEs include nausea, vomiting,
loss of appetite, or diarrhea. Pooled data of human subject’s
studies provides support for the hypothesis that TwHF use could
reduce weight gain risk compare with Prednisone which is often
used in RA patient treatment. These results should be carefully
interpreted and need to be explored through further research.
LIMITATIONS
The main limitation of this study is highly variable in study types.
594 studies were published over the entire period from 1979 to
2015 (Figure 2). Diagnostic criteria, treatments and accuracy of
measurements of physiological parameters have changed during
that period. Although we find combination therapy has potential
advantages, the determination of the heterogeneity between
drugs combination is still a question in meta-analyses (Safdar
et al., 2004). We deal with heterogeneity among the studies in
numerous ways: (1) we used a random-effects model to do the
analysis because it takes into account the heterogeneity of the
various studies, (2) we excluded studies with unclear information,
(3) and we also excluded retrospective data in combined analysis.
But even so, we cannot be certain that the heterogeneity in the
intervention groups and the control groups did not influence the
estimates. In our study, only under the appropriate conditions,
we combined to produce ORs.
Moreover, because most CCTs and RCTs did not use a
patient group that was new to TwHF (or did not provide this
information), length of follow-up was usually poorly defined so
the average interval between first starting TwHF and the onset
of AEs is unknown. Furthermore, we could not obtain any exact
individual information of TwHF from China SFDA. According
to the national adverse drug reaction monitoring center case
report data, from Jan 2004 to Sep 2011, involving TwHF case
report 839 cases, serious in 73. Our analysis suggested different
incidences of AEs between controlled trial arms. The incidences
were always lower in treatment groups than in control arms.
Another limitation is the absence of the long-term cohort studies.
Dose information was incompletely reported and any potential
predictors of AE risk could not be specifically addressed in
meta-analysis.
Also, most studies did not provide appropriate information of
the number of TwHF specific AEs. For example, authors usually
reported gastrointestinal AE but did not provide information
about nausea or vomiting. Another unavoidable problem is that
most of included primary studies come from Chinese journals.
The major Chinese herbal researches are in China, and the
many original research results are mainly published in Chinese.
Since global researchers demand for TwHF relevant resources,
regardless the languages, then the data from China needs to
be included in the analysis. Compared with other Chinese
herbal medicines, TwHF has been explored in many excellent
international studies. Nonetheless, we were able to locate a
reasonable amount of evidence that allows cautious conclusions
to be drawn about the safety of TwHF.
CONCLUSION
Our findings suggest that slightly more than one-fourth of
patients who were taking TwHF had experienced AEs. A clear
need exists for improved understanding of contributing risk
factors, as well as of prevention and management strategies
to improve patients’ tolerance for TwHF. The effect estimates,
varying by specific study types, deserve further investigation.
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